ArticleThe American journal of pathology2004
Differential gene expression in ovarian carcinoma: identification of potential biomarkers.
Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 284 citations in OpenAlex.
- Identification of ovarian cancer metastatic miRNAs.PloS one · 2013Trial
- Advances in S100 protein family for gynecological malignancies.Discover oncology · 2025Review
- Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2024Review
- Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.Clinical proteomics · 2024Article
- Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.Frontiers in molecular biosciences · 2024Review
- Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival.Communications biology · 2023Article
- Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.International journal of molecular sciences · 2023Review
- S100A1 expression characterizes terminally differentiated superficial cells in the urothelium of the murine bladder and ureter.Histochemistry and cell biology · 2022Article
- Sphingosine 1-phosphate lyase facilitates cancer progression through converting sphingolipids to glycerophospholipids.Clinical and translational medicine · 2022Article
- Article
- Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib.Journal of oncology · 2022Article
- Claudins as biomarkers of differential diagnosis and prognosis of tumors.Journal of cancer research and clinical oncology · 2021Review
- Ovarian Cancer: Biomarkers and Targeted Therapy.Biomedicines · 2021Review
- Transient commensal clonal interactions can drive tumor metastasis.Nature communications · 2020Article
- Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- Sphingosine Kinases are Involved in Macrophage NLRP3 Inflammasome Transcriptional Induction.International journal of molecular sciences · 2020Article
- Inhibition of Ovarian Cancer Cell Spheroid Formation by Synthetic Peptides Derived from Nectin-4.International journal of molecular sciences · 2020Article
- Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening.Scientific reports · 2019Article
- Calpain system protein expression and activity in ovarian cancer.Journal of cancer research and clinical oncology · 2019Article
- Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing approximately 12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the beta8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX alpha2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein A1. Statistical analyses showed that the beta8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.